 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
SUMMARIES FOR PATIENTS
Drug Resistance Tests to Predict Response to Treatment for HIV Infection
7 December 1999 | Volume 131 Issue 11 | Page 813
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine.
The summary below is from the full report titled "HIV-1 Genotypic Resistance Patterns Predict Response to saquinavir–ritonavir Therapy in Patients in Whom Previous Protease Inhibitor Therapy Had Failed." It is in the 7 December 1999 issue of Annals of Internal Medicine (volume 131, pages 813-821). The authors are A.R. Zolopa, R.W. Shafer, A. Warford, J.G. Montoya, P. Hsu, D. Katzenstein, T.C. Merigan, and B. Efron.
What is the problem and what is known about it so far?
The human immunodeficiency virus (HIV, the virus that causes AIDS) often becomes resistant to drug treatment. "Resistant" means that the virus's genes have changed so that the available drugs no longer work to destroy it. Special tests for resistance to anti-HIV drugs have recently become available. However, it is not really known whether these tests can help doctors predict which patients will respond to HIV drug treatment.
Why did the researchers do this particular study?
They wanted to find out whether testing for resistance to anti-HIV drugs could help predict which patients would or would not respond to further anti-HIV medicines.
Who was studied?
Fifty-four patients in the HIV clinic of a California teaching hospital were evaluated. Treatment with certain highly active anti-HIV drugs had already stopped working in these patients. The patients were about start receiving a new combination of two drugs, saquinavir and ritonavir, that they had not yet received.
How was the study done?
The researchers did resistance tests on virus obtained from the patients before they started taking the new drugs. They also collected information about the patients that might be helpful in predicting the response to drug therapy: for example, what anti-HIV drugs patients had taken in the past, how often they missed doses of medication, and how advanced the HIV infection was at the time they began the new treatment. They then followed patients to see who responded to the new treatment after 12 and 26 weeks, and who did not.
What did they researchers find?
Only 22 of the 54 patients were responding to the new drugs by week 12, and only 12 were responding by week 26. A previous diagnosis of AIDS, more severe disease at the time the new therapy was started, and the number of different HIV medicines a patient had taken in the past were all helpful in predicting who would respond. Even accounting for these other factors, however, the resistance tests done on the virus itself at the time patients started the new drugs were the best predictors of who would respond to therapy.
What were the limitations of the study?
The number of patients studied was small, and they all came from a single clinic. In addition, only patients receiving one particular anti-HIV medication regimen were studied.
What are the study's implications?
The results of this study support the idea that testing the HIV virus from individual patients for HIV drug resistance might be useful in predicting which patients will and which will not respond to certain types of HIV drug treatment. Many other similar studies will be needed, however, before virus resistance testing can be widely accepted.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  G. S. Zaric, A. M. Bayoumi, M. L. Brandeau, and D. K. Owens The Cost-Effectiveness of Counseling Strategies to Improve Adherence to Highly Active Antiretroviral Therapy among Men Who Have Sex with Men Med Decis Making, June 1, 2008; 28(3): 359 - 376. [Abstract] [PDF]
|
|
|
|
 |
|
 A. F. Y. Poon, S. L. Kosakovsky Pond, D. D. Richman, and S. D. W. Frost Mapping Protease Inhibitor Resistance to Human Immunodeficiency Virus Type 1 Sequence Polymorphisms within Patients J. Virol., December 15, 2007; 81(24): 13598 - 13607. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Y. W. Tong, J. Mullen, R. Kulasegaram, A. De Ruiter, S. O'Shea, and I. L. Chrystie Genotyping of B and Non-B Subtypes of Human Immunodeficiency Virus Type 1 J. Clin. Microbiol., September 1, 2005; 43(9): 4623 - 4627. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.-G. Marcelin, I. Cohen-Codar, M. S. King, P. Colson, E. Guillevic, D. Descamps, C. Lamotte, V. Schneider, J. Ritter, M. Segondy, et al. Virological and Pharmacological Parameters Predicting the Response to Lopinavir-Ritonavir in Heavily Protease Inhibitor-Experienced Patients Antimicrob. Agents Chemother., May 1, 2005; 49(5): 1720 - 1726. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Scott Simplifying the treatment of HIV infection with ritonavir-boosted protease inhibitors in antiretroviral-experienced patients Am. J. Health Syst. Pharm., April 15, 2005; 62(8): 809 - 815. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. D. Sanders, A. M. Bayoumi, V. Sundaram, S. P. Bilir, C. P. Neukermans, C. E. Rydzak, L. R. Douglass, L. C. Lazzeroni, M. Holodniy, and D. K. Owens Cost-Effectiveness of Screening for HIV in the Era of Highly Active Antiretroviral Therapy N. Engl. J. Med., February 10, 2005; 352(6): 570 - 585. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.-G. Marcelin, C. Dalban, G. Peytavin, C. Lamotte, R. Agher, C. Delaugerre, M. Wirden, F. Conan, S. Dantin, C. Katlama, et al. Clinically Relevant Interpretation of Genotype and Relationship to Plasma Drug Concentrations for Resistance to Saquinavir-Ritonavir in Human Immunodeficiency Virus Type 1 Protease Inhibitor-Experienced Patients Antimicrob. Agents Chemother., December 1, 2004; 48(12): 4687 - 4692. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Mo, L. Lu, R. Pithawalla, D. J. Kempf, and A. Molla Complementation in Cells Cotransfected with a Mixture of Wild-Type and Mutant Human Immunodeficiency Virus (HIV) Influences the Replication Capacities and Phenotypes of Mutant Variants in a Single-Cycle HIV Resistance Assay J. Clin. Microbiol., September 1, 2004; 42(9): 4169 - 4174. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. Garcia-Lerma, H. MacInnes, D. Bennett, H. Weinstock, and W. Heneine Transmitted Human Immunodeficiency Virus Type 1 Carrying the D67N or K219Q/E Mutation Evolves Rapidly to Zidovudine Resistance In Vitro and Shows a High Replicative Fitness in the Presence of Zidovudine J. Virol., July 15, 2004; 78(14): 7545 - 7552. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Gonzalez, B. Masquelier, H. Fleury, B. Lacroix, A. Troesch, G. Vernet, and J. N. Telles Detection of Human Immunodeficiency Virus Type 1 Antiretroviral Resistance Mutations by High-Density DNA Probe Arrays J. Clin. Microbiol., July 1, 2004; 42(7): 2907 - 2912. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Clotet and P. R. Skolnik Comparison of Regimens as Initial Therapy for HIV N. Engl. J. Med., March 4, 2004; 350(10): 1053 - 1054. [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Katzenstein Genotype, Phenotype, and Virtual Phenotype: Who Needs What and Why? J Int Assoc Physicians AIDS Care (Chic Ill), October 1, 2003; 2(4): 140 - 146. [PDF]
|
|
|
|
|
|
R. A. Galli, B. Sattha, B. Wynhoven, M. V. O'Shaughnessy, and P. R. Harrigan Sources and Magnitude of Intralaboratory Variability in a Sequence-Based Genotypic Assay for Human Immunodeficiency Virus Type 1 Drug Resistance J. Clin. Microbiol., July 1, 2003; 41(7): 2900 - 2907. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Grant, D. R. Kuritzkes, V. A. Johnson, J. W. Mellors, J. L. Sullivan, R. Swanstrom, R. T. D'Aquila, M. Van Gorder, M. Holodniy, R. M. Lloyd Jr., et al. Accuracy of the TRUGENE HIV-1 Genotyping Kit J. Clin. Microbiol., April 1, 2003; 41(4): 1586 - 1593. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Kuritzkes, R. M. Grant, P. Feorino, M. Griswold, M. Hoover, R. Young, S. Day, R. M. Lloyd Jr., C. Reid, G. F. Morgan, et al. Performance Characteristics of the TRUGENE HIV-1 Genotyping Kit and the Opengene DNA Sequencing System J. Clin. Microbiol., April 1, 2003; 41(4): 1594 - 1599. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Watkins, W. Resch, D. Irlbeck, and R. Swanstrom Selection of High-Level Resistance to Human Immunodeficiency Virus Type 1 Protease Inhibitors Antimicrob. Agents Chemother., February 1, 2003; 47(2): 759 - 769. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Aslanzadeh HIV Resistance Testing: an Update Ann. Clin. Lab. Sci., October 1, 2002; 32(4): 406 - 413. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Little, S. Holte, J.-P. Routy, E. S. Daar, M. Markowitz, A. C. Collier, R. A. Koup, J. W. Mellors, E. Connick, B. Conway, et al. Antiretroviral-Drug Resistance among Patients Recently Infected with HIV N. Engl. J. Med., August 8, 2002; 347(6): 385 - 394. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. G. Yeni, S. M. Hammer, C. C. J. Carpenter, D. A. Cooper, M. A. Fischl, J. M. Gatell, B. G. Gazzard, M. S. Hirsch, D. M. Jacobsen, D. A. Katzenstein, et al. Antiretroviral Treatment for Adult HIV Infection in 2002: Updated Recommendations of the International AIDS Society-USA Panel JAMA, July 10, 2002; 288(2): 222 - 235. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Molla, H. Mo, S. Vasavanonda, L. Han, C. T. Lin, A. Hsu, and D. J. Kempf In Vitro Antiviral Interaction of Lopinavir with Other Protease Inhibitors Antimicrob. Agents Chemother., July 1, 2002; 46(7): 2249 - 2253. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Servais, C. Lambert, J.-M. Plesseria, E. Fontaine, I. Robert, V. Arendt, T. Staub, R. Hemmer, F. Schneider, and J.-C. Schmit Longitudinal Use of a Line Probe Assay for Human Immunodeficiency Virus Type 1 Protease Predicts Phenotypic Resistance and Clinical Progression in Patients Failing Highly Active Antiretroviral Therapy Antimicrob. Agents Chemother., June 1, 2002; 46(6): 1928 - 1933. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. W. Shafer Genotypic Testing for Human Immunodeficiency Virus Type 1 Drug Resistance Clin. Microbiol. Rev., April 1, 2002; 15(2): 247 - 277. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Kantor, W. J. Fessel, A. R. Zolopa, D. Israelski, N. Shulman, J. G. Montoya, M. Harbour, J. M. Schapiro, and R. W. Shafer Evolution of Primary Protease Inhibitor Resistance Mutations during Protease Inhibitor Salvage Therapy Antimicrob. Agents Chemother., April 1, 2002; 46(4): 1086 - 1092. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 HIV Drug Resistance Testing: An Update for the Clinician AIDS Clinical Care, October 1, 2001; 2001(1001): 8 - 8. [Full Text]
|
|
|
|
|
|
D. J. Kempf, J. D. Isaacson, M. S. King, S. C. Brun, Y. Xu, K. Real, B. M. Bernstein, A. J. Japour, E. Sun, and R. A. Rode Identification of Genotypic Changes in Human Immunodeficiency Virus Protease That Correlate with Reduced Susceptibility to the Protease Inhibitor Lopinavir among Viral Isolates from Protease Inhibitor-Experienced Patients J. Virol., August 15, 2001; 75(16): 7462 - 7469. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Erali, S. Page, L. G. Reimer, and D. R. Hillyard Human Immunodeficiency Virus Type 1 Drug Resistance Testing: a Comparison of Three Sequence-Based Methods J. Clin. Microbiol., June 1, 2001; 39(6): 2157 - 2165. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J Little Is transmitted drug resistance in HIV on the rise? BMJ, May 5, 2001; 322(7294): 1074 - 1075. [Full Text]
|
|
|
|
|
|
R. W. Shafer, K. Hertogs, A. R. Zolopa, A. Warford, S. Bloor, B. J. Betts, T. C. Merigan, R. Harrigan, and B. A. Larder High Degree of Interlaboratory Reproducibility of Human Immunodeficiency Virus Type 1 Protease and Reverse Transcriptase Sequencing of Plasma Samples from Heavily Treated Patients J. Clin. Microbiol., April 1, 2001; 39(4): 1522 - 1529. [Abstract] [Full Text]
|
|
|
|
|
|
J. Servais, C. Lambert, E. Fontaine, J.-M. Plesséria, I. Robert, V. Arendt, T. Staub, F. Schneider, R. Hemmer, G. Burtonboy, et al. Comparison of DNA Sequencing and a Line Probe Assay for Detection of Human Immunodeficiency Virus Type 1 Drug Resistance Mutations in Patients Failing Highly Active Antiretroviral Therapy J. Clin. Microbiol., February 1, 2001; 39(2): 454 - 459. [Abstract] [Full Text]
|
|
|
|
 |
|
 P. Flowers Gay Men and HIV/AIDS Risk Management Health (London) , January 1, 2001; 5(1): 50 - 75. [Abstract] [PDF]
|
|
|
|
 |
|
 R. Sharma Antiretroviral Resistance: Mechanisms, Detection and Clinical Implications Journal of Pharmacy Practice, December 1, 2000; 13(6): 442 - 456. [Abstract] [PDF]
|
|
|
|
|
|
M. S. Hirsch, F. Brun-Vezinet, R. T. D'Aquila, S. M. Hammer, V. A. Johnson, D. R. Kuritzkes, C. Loveday, J. W. Mellors, B. Clotet, B. Conway, et al. Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection: Recommendations of an International AIDS Society-USA Panel JAMA, May 10, 2000; 283(18): 2417 - 2426. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Petropoulos, N. T. Parkin, K. L. Limoli, Y. S. Lie, T. Wrin, W. Huang, H. Tian, D. Smith, G. A. Winslow, D. J. Capon, et al. A Novel Phenotypic Drug Susceptibility Assay for Human Immunodeficiency Virus Type 1 Antimicrob. Agents Chemother., April 1, 2000; 44(4): 920 - 928. [Abstract] [Full Text]
|
|
|
|
|
|
J. E. Gallant Strategies for Long-term Success in the Treatment of HIV Infection JAMA, March 8, 2000; 283(10): 1329 - 1334. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Genotype Testing and Response to Therapy AIDS Clinical Care, February 1, 2000; 2000(201): 4 - 4. [Full Text]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article
